SBP GROUP (01177.HK): TQ-A3334 20.8% HBsAg clearance at week 48
- The high dose cut HBsAg by 1.3244 and 1.8103 log10 IU/mL at weeks 24 and 48 (both P<0.0001), while other dose groups showed no significant decline.
- At week 48, 58.3% of the high-dose group were below 100 IU/mL, with 5/24 (20.8%) clearing HBsAg and 4/24 (16.7%) seroconverting.
NewTimeSpace News: On 9 November 2026, Sino Biopharmaceutical Limited (Stock Code: 01177) said TQ-A3334, an in-house class 1 drug of subsidiary Chia Tai Tianqing, was presented orally at the AASLD 2026 late-breaking session with phase II results. The selective oral TLR7 agonist restores exhausted innate and adaptive immunity and was combined with nucleos(t)ide analogues (NAs) in chronic hepatitis B.
The double-blind, placebo-controlled trial (NCT06706310) enrolled 81 NA-treated patients, 12/24/24 across dose groups and 21 on placebo. At weeks 24 and 48 the high dose cut HBsAg by 1.3244 and 1.8103 log10 IU/mL (both P<0.0001), with 58.3% below 100 IU/mL, 5/24 (20.8%) clearing HBsAg and 4/24 (16.7%) seroconverting, and none elsewhere. In those with baseline HBsAg up to 1,000 IU/mL the fall was 2.0985 log10, with 26.3% clearance. TRAEs hit 91.67% of the high-dose group and grade 3+ 37.50%, with no grade 4/5 events or deaths. CDE granted breakthrough designation in October 2026.
- SBP GROUP (01177.HK): Boehringer deal worth up to US$7bn
- SBP GROUP (01177.HK): Two Hepatitis B Drugs Granted CDE Breakthrough Therapy Status
- SBP GROUP (01177.HK): TQB2102 Data at ESMO; Phase III Breast Cancer Median PFS 16.4 Months
- SBP GROUP (01177.HK): TQC2731 Phase III fully enrolled in CRSwNP
- SBP GROUP (01177.HK): TQ-A3334, Bepirovirsen Data Picked for AASLD
